Can Horizon Pharma (HZNP) Run Higher on Strong Earnings Estimate Revisions?

Zacks

Horizon Pharma plc HZNP is a specialty biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on HZNP’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Horizon Pharma could be a solid choice for investors.

Current Quarter Estimates for HZNP

In the past 30 days, 1 estimate has gone higher for Horizon Pharma while no estimate has been revised lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 44 cents a share 30 days ago, to 70 cents today, a move of 59.1%.

Current Year Estimates for HZNP

Meanwhile, Horizon Pharma’s current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to none moving lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.25 per share 30 days ago to $1.67 per share today, an increase of 33.6%.

Bottom Line

The stock has also started to move higher lately, adding 24.5% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research

Be the first to comment

Leave a Reply